Zenosense, Inc. (ZENO) Provides Update on Staph Infection Detection Device’s Development

Today before the opening bell, Zenosense shared an update regarding its device for the detection of the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug”, which is also known as staph infection. Since the company signed the development agreement with its partner and a leading European sensor detector, the Sgenia Group, six months ago, notable progress has been made.

Since the device’s development commenced in December 2013, a number of things have been completed:

•           A technical review of volatile organic compounds produced by MSSA (Methicillin-susceptible S.aureus) and MRSA in vitro or exhaled breath has been undertaken. Several compounds, including compounds that could be used to distinguish MSSA and MRSA, were identified to have potential for identifying S. areus from background VOCs produced by smoking and natural flora.

•           A comprehensive work plan and laboratory protocols were established using gold-standard gas chromatography/mass spectrometry techniques and solid phase micro extraction.

•           Some testing has been successfully completed, which consists of identifying the target VOCs in the headspace above a contained bacterial culture; correlating target VOCs with exhaled breath. in infected patients with S. areus; and detecting those VOCs with an appropriate gas sensor.

•           An in-depth review for determination of suitable gas sensors for infection detection has been conducted.

•           Efforts are underway to enhance sensor sensibility and specificity capabilities.

•           Significant progress has been made on development of complex algorithmic processing for reduction of interference from unrelated VOCs and increase detection of S. areus-specific signature VOCs.

•           Data from the gold-standard gas chromatography/mass spectrometry research continues to be analyzed for identifying any other S. areus compounds, which could be used to detect the presence of MSSA and MRSA in exhaled breath.

•           In the six-month space, collaboration agreements and partnerships have been established with relevant hospitals, universities, and a private laboratory in the various fields of sensors, polymer electrochemistry, microbiology, infectious disease, pneumology, chromatography, and microorganism identification.

•           Next steps will be to commence laboratory experiments with coagulase-negative Staphylococci strains and hospital experiments with clinical MRSA, MSSA and coagulase-negative Staphylococci strains.

Much more information about the sensor device’s development and the emerging market potential for Zenosense’s potentially groundbreaking detection technology can be found at: www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net